BiopharmaCAPR

Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell and exosome therapies, with its lead cardiosphere-derived cell product deramiocel (CAP-1002) focused on the skeletal and cardiac manifestations of Duchenne muscular dystrophy.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Capricor Therapeutics forecasting benchmarks

1 benchmark

ResolvedPhase 3

HOPE-3 Phase 3: deramiocel (CAP-1002) Duchenne muscular dystrophy (DMD)

Deramiocel · Duchenne muscular dystrophy

Clinical Trials

Pipeline on the platform

Deramiocel· Allogeneic cardiosphere-derived cell therapy

Therapeutic areas

Duchenne muscular dystrophy· DMD

About Capricor Therapeutics

What is Capricor Therapeutics developing?

Which Capricor Therapeutics trials can I forecast?

We track 1 Capricor Therapeutics trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes